Liraglutide

Sort by

Des-Ala(2)-Liraglutide

  • CAT NUMBER DCTI-D-200
  • CAS NUMBER NA
  • MOLECULAR FORMULA C169H260N42O50
  • MOLECULAR WEIGHT 3680.18

Des-Gly (29)-Liraglutide

  • CAT NUMBER DCTI-D-140
  • CAS NUMBER NA
  • MOLECULAR FORMULA C170H262N42O50
  • MOLECULAR WEIGHT 3694.21

Des-Gly (4)-Liraglutide

  • CAT NUMBER DCTI-D-138
  • CAS NUMBER NA
  • MOLECULAR FORMULA C170H262N42O50
  • MOLECULAR WEIGHT 3694.21

Des-Gly(31)-Liraglutide

  • CAT NUMBER DCTI-D-155
  • CAS NUMBER NA
  • MOLECULAR FORMULA C170H262N42O50
  • MOLECULAR WEIGHT 3694.21

Des-His(1)-Liraglutide

  • CAT NUMBER DCTI-D-227
  • CAS NUMBER NA
  • MOLECULAR FORMULA C166H258N40O50
  • MOLECULAR WEIGHT 3614.12

Des-Ser (8)-Liraglutide

  • CAT NUMBER DCTI-D-141
  • CAS NUMBER NA
  • MOLECULAR FORMULA C169H260N42O49
  • MOLECULAR WEIGHT 3664.18

Des-Thr(5)-Liraglutide

  • CAT NUMBER DCTI-D-193
  • CAS NUMBER NA
  • MOLECULAR FORMULA C168H258N42O49
  • MOLECULAR WEIGHT 3650.16

Des-Thr(7)-Liraglutide

  • CAT NUMBER DCTI-D-379
  • CAS NUMBER NA
  • MOLECULAR FORMULA C168H258N42O49
  • MOLECULAR WEIGHT 3650.16

Endo-Thr(7)-Liraglutide

  • CAT NUMBER DCTI-D-384
  • CAS NUMBER NA
  • MOLECULAR FORMULA C176H272N44O53
  • MOLECULAR WEIGHT 3852.37
LOAD MORE
You're viewed 36 of 52 products
References
FAQ's

Frequently Asked Questions

Liraglutide impurities can be identified using analytical methods such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), etc.

Liraglutide impurities can be purified after synthesis using various techniques such as preparative HPLC, flash chromatography, or crystallization. These methods involve separating the impurities from the main product based on their chemical properties and physical characteristics.

Liraglutide impurities should be stored at recommended temperature conditions, typically 2-8°C or -20°C, depending on their stability. Improper storage can lead to degradation and loss of purity, so it's important to follow the manufacturer's instructions.

Liraglutide impurities can affect drug efficacy and safety. It is observed that impurities can cause adverse effects such as allergic reactions, injection site reactions, gastrointestinal disturbances, pancreatitis, or liver damage due to their toxicity or carcinogenic nature. Identifying and quantifying the impurities is essential during drug development.

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart